Novel study emphasizes the need for improved training to recognize key behavior differences in this patient population

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition on December 8.

Find info about: VMP's essay contest for students, VEC's new YouTube channel and video series, a new critical thinking resource, and when politicization of science results in lack of access to healthcare resources.

See how well you do answering questions about information shared in 2024 Parents PACK newsletter articles.

Risk of transmission of the rotavirus vaccine is extremely low and poses very minimal risk to NICU babies

In recognition of her impact on child health in Consuelo and beyond, Ramona Cordero was awarded the inaugural Melissa Ketunuti Basselier Prize in Global Child Health.

This study aims to expand use of supraglottic airways as a potential approach for better outcomes for newborns who require resuscitation

The Lactation Department of the Children’s Hospital of Philadelphia (CHOP) offers a bi-annual internship to individuals who are preparing to take the International Board Lactation Consultant Exam.

The study from the COVID-19 International Research Team may also explain a potential cause of “long COVID”

CHOP Alumni celebrated the winners of the 2024 CHOP Alumni Awards and mourned a tragic loss. See details.